Stocktoria
AbCellera Biologics Inc. ABCL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-12-11
AbCellera Biologics Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M |
| R&D expense | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M |
| Operating income | -$217.1M | -$314.8M | -$237.2M | $216.5M | $204.4M |
| Income tax | -$31.2M | -$37.5M | -$27.6M | $80.6M | $65.7M |
| Net income | -$146.4M | -$162.9M | -$146.4M | $158.5M | $153.5M |
| EPS (diluted) | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 |
| Operating cash flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $244.6M |
| Free cash flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | $186.1M |
| Cash & equivalents | $61.8M | $55.6M | $52.2M | $44.9M | $8.2M |
| Inventory | $6.3M | $0 | — | — | — |
| Total assets | $1.4B | $1.4B | $1.5B | $1.5B | $1.3B |
| Total liabilities | $390.0M | $304.5M | $335.8M | $307.6M | $292.8M |
| Shareholders' equity | $966.9M | $1.1B | $1.2B | $1.2B | $1.0B |
Source: SEC EDGAR filings · CIK 0001703057 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.